Watch VTVT. Know when insiders buy.
One email the day a filing lands. Free.
VTVT
vTv Therapeutics Inc.
30.57
−1.28 −4.02%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
55
WATCH · shorts 55
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $36.8M +216600.0%NET INCOME −$4.8MNET CASH $81.6M52W 20.23 – 42.72SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$13.9M | −$13.1M | — | — | −$11.4M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $36.8M | — | — | $23.3M | $24.1M | — | — | $9.2M | — | — | May 13 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$7.9M | −$7.1M | — | — | −$9.3M | — | — | Mar 10 |
| Q3 2025 · Sep 30 | $0 | — | — | −$10.7M | −$8.7M | — | — | −$5.2M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$7.7M | −$6M | — | — | −$5.1M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$6.5M | −$5.1M | — | — | −$5.7M | — | — | May 13 |
| Q4 2024 · Dec 31derived | $17K | — | — | −$4.9M | −$3.6M | — | — | −$4.8M | — | — | Mar 10 |
| Q3 2024 · Sep 30 | $0 | — | — | −$6.5M | −$4.8M | — | — | −$6.4M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$7.2M | −$5.2M | — | — | −$6.7M | — | — | Aug 12 |
| Q1 2024 · Mar 31 | $1M | — | — | −$5.6M | −$4.9M | — | — | −$7.3M | — | — | May 15 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$4.7M | −$3.5M | — | — | −$2.9M | $0 | −$2.9M | Mar 10 |
| Q3 2023 · Sep 30 | $0 | — | — | −$5.4M | −$6.7M | — | — | −$4.8M | $0 | −$4.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$32.8M | −$27M | — | — | −$25.3M | — | — | — | — |
| FY2024 · to Dec 31 | $1M | — | −$24.2M | −$18.5M | -1815.3% | — | −$25.3M | $0 | −$25.3M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$25.5M | −$20.3M | — | — | −$19.1M | $0 | −$19.1M | — | — |
| FY2022 · to Dec 31 | $2M | — | −$22.5M | −$19.2M | -949.7% | — | −$16M | $21K | −$16M | — | — |
| FY2021 · to Dec 31 | $4M | — | −$21.7M | −$13M | -324.3% | — | −$19.3M | $0 | −$19.3M | — | — |
| FY2020 · to Dec 31 | $6.4M | — | −$11.9M | −$8.5M | -132.5% | — | −$18M | $0 | −$18M | — | — |
Every number comes from vTv Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.